Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1443-1447

  Kano, Masanobu ^a   Tsukahara, Tomohide ^a   Emori, Makoto ^a   Murase, Masaki ^a   Torigoe, Toshihiko ^a   Kawaguchi, Satoshi ^a   Wada, Takuro ^a   Yamashita, Toshihiko ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MALIGNANT FIBROUS HISTIOCYTOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL CLONING; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DILUTION; HUMAN; HUMAN CELL; MALIGNANT FIBROUS HISTIOCYTOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIDE POPULATION CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

BONE NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASTIC STEM CELLS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79960418939     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01962.x     Document Type: Article

References (20)

1. Steiner GC, Jundt G, Martignetti JA. Pathology and genetics of tumors of soft tissue and bone. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumors. Lyon: IARC Press, 2002; 294-6.
2. Capanna R, Bertoni F, Bacchini P, Bacci G, Guerra A, Campanacci M. Malignant fibrous histiocytoma of bone. The experience at the Rizzoli Institute: report of 90 cases. Cancer 1984; 54: 177-87.
3. Bielack SS, Schroeders A, Fuchs N et al. Malignant fibrous histiocytoma of bone: a retrospective EMSOS study of 125 cases. European Musculo-Skeletal Oncology Society. Acta Orthop Scand 1999; 70: 353-60.
4. Bramwell VH, Steward WP, Nooij M et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: aEuropean Osteosarcoma Intergroup study. J Clin Oncol 1999; 17: 3260-9.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
6. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
7. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-45.
8. Bleau AM, Hambardzumyan D, Ozawa T et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-35.
9. Tsukahara T, Torigoe T, Tamura Y et al. Antigenic peptide vaccination: Provoking immune response and clinical benefit for cancer. Curr Immunol Rev 2008; 4: 235-41.
10. Murase M, Kano M, Tsukahara T et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer 2009; 101: 1425-32.
11. Tsukahara T, Kawaguchi S, Ida K et al. HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node. J Orthop Res 2006; 24: 94-101.
12. Pellegatta S, Poliani PL, Corno D et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006; 66: 10247-52.
13. Todaro M, D'Asaro M, Caccamo N et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182: 7287-96.
14. Pietra G, Manzini C, Vitale M et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 2009; 21: 793-801.
15. Weng D, Song B, Durfee J et al. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer 2010; doi: 10.1002/ijc.25851 [Epub ahead of print].
16. Seliger B. Strategies of tumor immune evasion. BioDrugs 2005; 19: 347-54.
17. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
18. Tsukahara T, Kawaguchi S, Torigoe T et al. Prognostic significance of HLA Class I expression in osteosarcoma defined by anti-pan HLA Class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 1374-80.
19. Yabe H, Tsukahara T, Kawaguchi S et al. Prognostic significance of HLA Class I expression in Ewing's sarcoma family of tumors. J Surg Oncol 2011; 103: 380-5.
20. Roesch A, Fukunaga-Kalabis M, Schmidt EC et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141: 583-94.